Antoni Ribas

162.0k total citations · 30 hit papers
551 papers, 61.0k citations indexed

About

Antoni Ribas is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Antoni Ribas has authored 551 papers receiving a total of 61.0k indexed citations (citations by other indexed papers that have themselves been cited), including 416 papers in Oncology, 275 papers in Molecular Biology and 219 papers in Immunology. Recurrent topics in Antoni Ribas's work include Cancer Immunotherapy and Biomarkers (232 papers), CAR-T cell therapy research (213 papers) and Melanoma and MAPK Pathways (211 papers). Antoni Ribas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (232 papers), CAR-T cell therapy research (213 papers) and Melanoma and MAPK Pathways (211 papers). Antoni Ribas collaborates with scholars based in United States, Australia and France. Antoni Ribas's co-authors include Jedd D. Wolchok, Siwen Hu‐Lieskovan, Jennifer A. Wargo, Padmanee Sharma, Keith T. Flaherty, Grant A. McArthur, Georgina V. Long, Jeffrey A. Sosman, Anusha Kalbasi and Roger S. Lo and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Antoni Ribas

539 papers receiving 60.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer immunotherapy using checkpoint blockade

2018 4.6k citations Antoni Ribas et al. profile →
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

2017 3.7k citations Padmanee Sharma, Siwen Hu‐Lieskovan et al. profile →
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Antoni Ribas, Jeffrey A. Sosman et al. profile →
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

2017 2.3k citations Antoni Ribas et al. profile →
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

2010 1.9k citations Antoni Ribas et al. profile →
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 1.6k citations Hubing Shi, Xiangju Kong et al. profile →
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 1.5k citations Antoni Ribas et al. profile →
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

2012 1.4k citations Paul B. Chapman, David B. Solit et al. profile →
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

2017 1.3k citations Ángel García-Díaz, Blanca Homet Moreno et al. profile →
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Antoni Ribas, F. Stephen Hodi et al. profile →
Classifying Cancers Based on T-cell Infiltration and PD-L1

2015 1.1k citations Antoni Ribas et al. Cancer Research profile →
Tumour-intrinsic resistance to immune checkpoint blockade

2019 1.0k citations Anusha Kalbasi, Antoni Ribas profile →
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

2017 898 citations Antoni Ribas, Georgina V. Long et al. profile →
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

2012 884 citations Antoni Ribas et al. profile →
Targeted agents and immunotherapies: optimizing outcomes in melanoma

2017 869 citations Antoni Ribas, Georgina V. Long et al. profile →
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2019 768 citations Antoni Ribas, Christian U. Blank et al. profile →
Combination cancer immunotherapies tailored to the tumour microenvironment

2015 738 citations Antoni Ribas et al. profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations F. Stephen Hodi, Wen‐Jen Hwu et al. profile →
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Douglas B. Johnson, Jeffrey A. Sosman et al. profile →
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

2018 583 citations Jennifer Tsoi, Lídia Robert et al. profile →
The “cancer immunogram”

2016 540 citations Christian U. Blank, John B.A.G. Haanen et al. profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
Adaptive Immune Resistance: How Cancer Protects from Immune Attack

2015 456 citations Antoni Ribas Cancer Discovery profile →
Melanoma

2015 441 citations Dirk Schadendorf, Antoni Ribas et al. profile →
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanoma

2015 435 citations Siwen Hu‐Lieskovan, Stephen Mok et al. profile →
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

2014 427 citations Jennifer Tsoi, Lídia Robert et al. profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. profile →
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

2018 275 citations Giulia Parisi, Antoni Ribas et al. profile →
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

2018 266 citations Anu Sharma, Sumit K. Subudhi et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Antoni Ribas

Since Specialization

Citations

This map shows the geographic impact of Antoni Ribas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoni Ribas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoni Ribas more than expected).

Fields of papers citing papers by Antoni Ribas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoni Ribas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoni Ribas. The network helps show where Antoni Ribas may publish in the future.

Co-authorship network of co-authors of Antoni Ribas

This figure shows the co-authorship network connecting the top 25 collaborators of Antoni Ribas. A scholar is included among the top collaborators of Antoni Ribas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoni Ribas. Antoni Ribas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ERK mediates interferon gamma-induced melanoma cell death 2023 ·Molecular Cancer ·Ameya S. Champhekar, (unknown), Justin D. Saco, (unknown), (unknown), (unknown), (unknown), June Lee, (unknown), Egmidio Medina, Katie M. Campbell, Daniel Karin, David Austin, (unknown), Antoni Ribas	14
2	Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade 2023 ·Journal for ImmunoTherapy of Cancer ·Luke Frankiw, Arun S. Singh, Cole W. Peters, Begoña Comı́n-Anduix, Beata Berent-Maoz, Mignonette H. Macabali, (unknown), (unknown), Paula Kaplan‐Lefko, Ignacio Baselga-Carretero, Antoni Ribas, Theodore S. Nowicki	11
3	Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade 2022 ·Cancer Research Communications ·Gabriel Abril-Rodríguez, Davis Y. Torrejon, Daniel Karin, Katie M. Campbell, Egmidio Medina, Justin D. Saco, (unknown), Ameya S. Champhekar, (unknown), Ignacio Baselga-Carretero, (unknown), Begoña Comı́n-Anduix, Cristina Puig-Saus, Antoni Ribas	8
4	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies 2021 ·Blood Cancer Discovery ·Antoni Ribas, Madhav V. Dhodapkar, Katie M. Campbell, Faith E. Davies, Steven D. Gore, Ronald Levy, Lee M. Greenberger	16
5	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response 2021 ·Proceedings of the National Academy of Sciences ·Anastasia Gangaev, Elisa A. Rozeman, Maartje W. Rohaan, Olga I. Isaeva, Daisy Philips, (unknown), Joost H. van den Berg, Antoni Ribas, Dirk Schadendorf, Bastian Schilling, Ton N. Schumacher, Christian U. Blank, John B.A.G. Haanen, Pia Kvistborg	21
6	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers breakdown → 2018 ·Clinical Cancer Research ·Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis M. Vence, Jennifer A. Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma	266
7	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study 2018 ·Clinical Cancer Research ·Michael B. Atkins, F. Stephen Hodi, John A. Thompson, Ray McDermott, Wen‐Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, (unknown), Shailender Bhatia, (unknown), Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas	48
8	SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study 2018 ·Cancer Discovery ·Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah Jean Lee Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung, Robert S. Janssen	237
9	Immunotherapy Resistance by Inflammation-Induced Dedifferentiation 2018 ·Cancer Discovery ·Arnav Mehta, Yeon Joo Kim, Lídia Robert, Jennifer Tsoi, Begoña Comı́n-Anduix, Beata Berent-Maoz, Alistair J. Cochran, James S. Economou, Paul C. Tumeh, Cristina Puig-Saus, Antoni Ribas	122
10	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells 2016 ·Cancer Immunology Research ·Blanca Homet Moreno, Jesse M. Zaretsky, Ángel García-Díaz, Jennifer Tsoi, Giulia Parisi, Lídia Robert, Katrina Meeth, Abibatou Ndoye, Marcus Bosenberg, Ashani T. Weeraratna, Thomas G. Graeber, Begoña Comı́n-Anduix, Siwen Hu‐Lieskovan, Antoni Ribas	104
11	Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma 2014 ·Clinical Cancer Research ·Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J. Wong, Lídia Robert, David Foulad, Michael Cerniglia, Bjoern Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, Antoni Ribas	285
12	CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire 2014 ·Clinical Cancer Research ·Lídia Robert, Jennifer Tsoi, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Thinle Chodon, Stephen Mok, Rong Huang, Alistair J. Cochran, Begoña Comı́n-Anduix, Richard C. Koya, Thomas G. Graeber, (unknown), Antoni Ribas	280
13	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence 2014 ·Cancer Research ·Moriah H. Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo J. Ramirez, Helen Won, Cailian Liu, Shakuntala Tiwari, Li Ren Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub, Antoni Ribas, Paul B. Chapman, Rona Yaeger, Barry S. Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit	219
14	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy breakdown → 2013 ·Cancer Discovery ·Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo	715
15	Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy 2013 ·Cancer Discovery ·Chao Ma, Ann Cheung, Thinle Chodon, Richard C. Koya, Zhongqi Wu, Charles Ng, Earl Avramis, Alistair J. Cochran, Owen N. Witte, David Baltimore, Bartosz Chmielowski, James S. Economou, Begonya Comin-Anduix, Antoni Ribas, James R. Heath	112
16	Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial 2011 ·Clinical Cancer Research ·Antoni Ribas, Jeffrey S. Weber, Bartosz Chmielowski, Begonya Comin-Anduix, (unknown), Michael Douek, Nagesh Ragavendra, Steve Raman, Elizabeth Seja, (unknown), (unknown), David C. Diamond, Zhiyong Qiu, (unknown), Adrian Bot	60
17	CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans 2011 ·Clinical Cancer Research ·Rong Huang, Jason Jalil, James S. Economou, Bartosz Chmielowski, Richard C. Koya, Stephen Mok, Hooman Sazegar, Elizabeth Seja, Arturo Villanueva, Jesús Gómez-Navarro, John A. Glaspy, Alistair J. Cochran, Antoni Ribas	120
18	Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses 2010 ·Proceedings of the National Academy of Sciences ·Richard C. Koya, Stephen Mok, Begoña Comı́n-Anduix, Thinle Chodon, Caius G. Radu, Michael I. Nishimura, Owen N. Witte, Antoni Ribas	48
19	T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy 2008 ·Clinical Cancer Research ·Dörthe Schaue, Begonya Comin-Anduix, Antoni Ribas, Li Zhang, Lee Goodglick, James Sayre, Annelies Debucquoy, Karin Haustermans, William H. McBride	115
20	Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade 2008 ·Clinical Cancer Research ·Antoni Ribas, Begoña Comı́n-Anduix, James S. Economou, Timothy R. Donahue, Pilar de la Rocha, Lilah F. Morris, Jason Jalil, Vivian B. Dissette, (unknown), John A. Glaspy, Jesús Gómez-Navarro, Alistair J. Cochran	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact